EP2888010 - METHODS FOR INHIBITING FASCIN [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 25.03.2022 Database last updated on 03.09.2024 | |
Former | The patent has been granted Status updated on 16.04.2021 | ||
Former | Grant of patent is intended Status updated on 16.12.2020 | ||
Former | Examination is in progress Status updated on 28.10.2020 | ||
Former | Grant of patent is intended Status updated on 17.06.2020 | ||
Former | Examination is in progress Status updated on 13.07.2018 | Most recent event Tooltip | 27.04.2024 | Lapse of the patent in a contracting state New state(s): MK | published on 29.05.2024 [2024/22] | Applicant(s) | For all designated states Cornell University Cornell Center for Technology, Enterprise & Commercialization 395 Pine Tree Road, Suite 310 Ithaca, NY 14850 / US | For all designated states Novita Pharmaceuticals, Inc. 1161 York Avenue 8C New York, NY 10065 / US | [2020/29] |
Former [2015/27] | For all designated states Cornell University 395 Pine Tree Road Ithaca, NY 14850 / US | ||
For all designated states Novita Pharmaceuticals Inc. 1161 York Avenue 8C New York, NY 10065 / US | Inventor(s) | 01 /
HUANG, Xin-yun 1161 York Avenue 8C New York, NY 10065 / US | 02 /
SHUE, Christy, Young 288 Alfred Avenue Englewood Cliffs, NJ 07632 / US | [2015/27] | Representative(s) | Barker Brettell LLP 100 Hagley Road Edgbaston Birmingham B16 8QQ / GB | [2021/20] |
Former [2015/27] | Atkinson, Jennifer Barker Brettell LLP 100 Hagley Road Edgbaston Birmingham B16 8QQ / GB | Application number, filing date | 13830441.5 | 21.08.2013 | [2021/20] | WO2013US55965 | Priority number, date | US201261692177P | 22.08.2012 Original published format: US 201261692177 P | US201361778015P | 12.03.2013 Original published format: US 201361778015 P | [2015/27] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2014031732 | Date: | 27.02.2014 | Language: | EN | [2014/09] | Type: | A2 Application without search report | No.: | EP2888010 | Date: | 01.07.2015 | Language: | EN | The application published by WIPO in one of the EPO official languages on 27.02.2014 takes the place of the publication of the European patent application. | [2015/27] | Type: | B1 Patent specification | No.: | EP2888010 | Date: | 19.05.2021 | Language: | EN | [2021/20] | Search report(s) | International search report - published on: | US | 01.05.2014 | (Supplementary) European search report - dispatched on: | EP | 22.06.2016 | Classification | IPC: | A61P35/00, A61P35/04, A61K31/428, A61K31/433, A61K31/522, C07D487/04 | [2016/14] | CPC: |
C07D487/04 (EP,US);
A61K31/428 (EP,US);
A61K31/433 (EP,US);
A61K31/522 (EP,US);
A61P25/00 (EP);
A61P25/28 (EP);
A61P29/00 (EP);
A61P31/04 (EP);
A61P31/12 (EP);
A61P35/00 (EP);
A61P35/02 (EP);
A61P35/04 (EP);
A61P9/00 (EP);
A61P9/10 (EP);
C07D249/12 (US);
C07D277/82 (US);
C07D285/08 (US);
C07D405/12 (US);
Y02A50/30 (EP)
(-)
|
Former IPC [2015/27] | A61P35/00, A61P35/04 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2015/27] | Extension states | BA | Not yet paid | ME | Not yet paid | Title | German: | VERFAHREN ZUR FASCINHEMMUNG | [2015/27] | English: | METHODS FOR INHIBITING FASCIN | [2015/27] | French: | MÉTHODES D'INHIBITION DE LA FASCINE | [2015/27] | Entry into regional phase | 27.02.2015 | National basic fee paid | 27.02.2015 | Search fee paid | 27.02.2015 | Designation fee(s) paid | 27.02.2015 | Examination fee paid | Examination procedure | 27.02.2015 | Examination requested [2015/27] | 17.01.2017 | Amendment by applicant (claims and/or description) | 16.07.2018 | Despatch of a communication from the examining division (Time limit: M06) | 24.01.2019 | Reply to a communication from the examining division | 12.04.2019 | Despatch of a communication from the examining division (Time limit: M06) | 22.10.2019 | Reply to a communication from the examining division | 18.06.2020 | Communication of intention to grant the patent | 28.10.2020 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 17.12.2020 | Communication of intention to grant the patent | 07.04.2021 | Fee for grant paid | 07.04.2021 | Fee for publishing/printing paid | 07.04.2021 | Receipt of the translation of the claim(s) | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 16.07.2018 | Opposition(s) | 22.02.2022 | No opposition filed within time limit [2022/17] | Fees paid | Renewal fee | 25.08.2015 | Renewal fee patent year 03 | 30.08.2016 | Renewal fee patent year 04 | 14.08.2017 | Renewal fee patent year 05 | 10.08.2018 | Renewal fee patent year 06 | 15.08.2019 | Renewal fee patent year 07 | 28.08.2020 | Renewal fee patent year 08 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 21.08.2013 | AL | 19.05.2021 | AT | 19.05.2021 | CY | 19.05.2021 | CZ | 19.05.2021 | EE | 19.05.2021 | FI | 19.05.2021 | HR | 19.05.2021 | LT | 19.05.2021 | LV | 19.05.2021 | MC | 19.05.2021 | MK | 19.05.2021 | PL | 19.05.2021 | RO | 19.05.2021 | RS | 19.05.2021 | SI | 19.05.2021 | SK | 19.05.2021 | SM | 19.05.2021 | BG | 19.08.2021 | NO | 19.08.2021 | GR | 20.08.2021 | LU | 21.08.2021 | IS | 19.09.2021 | PT | 20.09.2021 | [2024/22] |
Former [2023/30] | HU | 21.08.2013 | |
AL | 19.05.2021 | ||
AT | 19.05.2021 | ||
CY | 19.05.2021 | ||
CZ | 19.05.2021 | ||
EE | 19.05.2021 | ||
FI | 19.05.2021 | ||
HR | 19.05.2021 | ||
LT | 19.05.2021 | ||
LV | 19.05.2021 | ||
MC | 19.05.2021 | ||
PL | 19.05.2021 | ||
RO | 19.05.2021 | ||
RS | 19.05.2021 | ||
SI | 19.05.2021 | ||
SK | 19.05.2021 | ||
SM | 19.05.2021 | ||
BG | 19.08.2021 | ||
NO | 19.08.2021 | ||
GR | 20.08.2021 | ||
LU | 21.08.2021 | ||
IS | 19.09.2021 | ||
PT | 20.09.2021 | ||
Former [2023/29] | HU | 21.08.2013 | |
AL | 19.05.2021 | ||
AT | 19.05.2021 | ||
CZ | 19.05.2021 | ||
EE | 19.05.2021 | ||
FI | 19.05.2021 | ||
HR | 19.05.2021 | ||
LT | 19.05.2021 | ||
LV | 19.05.2021 | ||
MC | 19.05.2021 | ||
PL | 19.05.2021 | ||
RO | 19.05.2021 | ||
RS | 19.05.2021 | ||
SI | 19.05.2021 | ||
SK | 19.05.2021 | ||
SM | 19.05.2021 | ||
BG | 19.08.2021 | ||
NO | 19.08.2021 | ||
GR | 20.08.2021 | ||
LU | 21.08.2021 | ||
IS | 19.09.2021 | ||
PT | 20.09.2021 | ||
Former [2022/29] | AL | 19.05.2021 | |
AT | 19.05.2021 | ||
CZ | 19.05.2021 | ||
EE | 19.05.2021 | ||
FI | 19.05.2021 | ||
HR | 19.05.2021 | ||
LT | 19.05.2021 | ||
LV | 19.05.2021 | ||
MC | 19.05.2021 | ||
PL | 19.05.2021 | ||
RO | 19.05.2021 | ||
RS | 19.05.2021 | ||
SI | 19.05.2021 | ||
SK | 19.05.2021 | ||
SM | 19.05.2021 | ||
BG | 19.08.2021 | ||
NO | 19.08.2021 | ||
GR | 20.08.2021 | ||
LU | 21.08.2021 | ||
IS | 19.09.2021 | ||
PT | 20.09.2021 | ||
Former [2022/26] | AL | 19.05.2021 | |
AT | 19.05.2021 | ||
CZ | 19.05.2021 | ||
EE | 19.05.2021 | ||
FI | 19.05.2021 | ||
HR | 19.05.2021 | ||
LT | 19.05.2021 | ||
LV | 19.05.2021 | ||
MC | 19.05.2021 | ||
PL | 19.05.2021 | ||
RO | 19.05.2021 | ||
RS | 19.05.2021 | ||
SK | 19.05.2021 | ||
SM | 19.05.2021 | ||
BG | 19.08.2021 | ||
NO | 19.08.2021 | ||
GR | 20.08.2021 | ||
LU | 21.08.2021 | ||
IS | 19.09.2021 | ||
PT | 20.09.2021 | ||
Former [2022/23] | AT | 19.05.2021 | |
CZ | 19.05.2021 | ||
EE | 19.05.2021 | ||
FI | 19.05.2021 | ||
HR | 19.05.2021 | ||
LT | 19.05.2021 | ||
LV | 19.05.2021 | ||
MC | 19.05.2021 | ||
PL | 19.05.2021 | ||
RO | 19.05.2021 | ||
RS | 19.05.2021 | ||
SK | 19.05.2021 | ||
SM | 19.05.2021 | ||
BG | 19.08.2021 | ||
NO | 19.08.2021 | ||
GR | 20.08.2021 | ||
LU | 21.08.2021 | ||
IS | 19.09.2021 | ||
PT | 20.09.2021 | ||
Former [2022/18] | AT | 19.05.2021 | |
CZ | 19.05.2021 | ||
EE | 19.05.2021 | ||
FI | 19.05.2021 | ||
HR | 19.05.2021 | ||
LT | 19.05.2021 | ||
LV | 19.05.2021 | ||
MC | 19.05.2021 | ||
PL | 19.05.2021 | ||
RO | 19.05.2021 | ||
RS | 19.05.2021 | ||
SK | 19.05.2021 | ||
SM | 19.05.2021 | ||
BG | 19.08.2021 | ||
NO | 19.08.2021 | ||
GR | 20.08.2021 | ||
PT | 20.09.2021 | ||
IS | 22.12.2021 | ||
Former [2022/10] | AT | 19.05.2021 | |
CZ | 19.05.2021 | ||
EE | 19.05.2021 | ||
FI | 19.05.2021 | ||
HR | 19.05.2021 | ||
LT | 19.05.2021 | ||
LV | 19.05.2021 | ||
PL | 19.05.2021 | ||
RO | 19.05.2021 | ||
RS | 19.05.2021 | ||
SK | 19.05.2021 | ||
SM | 19.05.2021 | ||
BG | 19.08.2021 | ||
NO | 19.08.2021 | ||
GR | 20.08.2021 | ||
PT | 20.09.2021 | ||
IS | 22.12.2021 | ||
Former [2022/09] | AT | 19.05.2021 | |
CZ | 19.05.2021 | ||
FI | 19.05.2021 | ||
HR | 19.05.2021 | ||
LT | 19.05.2021 | ||
LV | 19.05.2021 | ||
PL | 19.05.2021 | ||
RO | 19.05.2021 | ||
RS | 19.05.2021 | ||
SK | 19.05.2021 | ||
SM | 19.05.2021 | ||
BG | 19.08.2021 | ||
NO | 19.08.2021 | ||
GR | 20.08.2021 | ||
IS | 19.09.2021 | ||
PT | 20.09.2021 | ||
Former [2022/07] | AT | 19.05.2021 | |
FI | 19.05.2021 | ||
HR | 19.05.2021 | ||
LT | 19.05.2021 | ||
LV | 19.05.2021 | ||
PL | 19.05.2021 | ||
RS | 19.05.2021 | ||
SM | 19.05.2021 | ||
BG | 19.08.2021 | ||
NO | 19.08.2021 | ||
GR | 20.08.2021 | ||
IS | 19.09.2021 | ||
PT | 20.09.2021 | ||
Former [2021/52] | AT | 19.05.2021 | |
FI | 19.05.2021 | ||
HR | 19.05.2021 | ||
LT | 19.05.2021 | ||
LV | 19.05.2021 | ||
PL | 19.05.2021 | ||
RS | 19.05.2021 | ||
BG | 19.08.2021 | ||
NO | 19.08.2021 | ||
GR | 20.08.2021 | ||
IS | 19.09.2021 | ||
PT | 20.09.2021 | ||
Former [2021/51] | AT | 19.05.2021 | |
FI | 19.05.2021 | ||
HR | 19.05.2021 | ||
LT | 19.05.2021 | ||
LV | 19.05.2021 | ||
RS | 19.05.2021 | ||
BG | 19.08.2021 | ||
NO | 19.08.2021 | ||
GR | 20.08.2021 | ||
IS | 19.09.2021 | ||
PT | 20.09.2021 | ||
Former [2021/50] | AT | 19.05.2021 | |
FI | 19.05.2021 | ||
HR | 19.05.2021 | ||
LT | 19.05.2021 | ||
LV | 19.05.2021 | ||
BG | 19.08.2021 | ||
NO | 19.08.2021 | ||
GR | 20.08.2021 | ||
PT | 20.09.2021 | ||
Former [2021/49] | AT | 19.05.2021 | |
FI | 19.05.2021 | ||
HR | 19.05.2021 | ||
LT | 19.05.2021 | ||
LV | 19.05.2021 | ||
BG | 19.08.2021 | ||
NO | 19.08.2021 | ||
GR | 20.08.2021 | ||
Former [2021/47] | AT | 19.05.2021 | |
FI | 19.05.2021 | ||
LT | 19.05.2021 | ||
BG | 19.08.2021 | ||
Former [2021/46] | AT | 19.05.2021 | |
FI | 19.05.2021 | ||
LT | 19.05.2021 | Documents cited: | Search | [X]WO0024725 (VERTEX PHARMA [US], et al) [X] 1,9-13 * p. 1, first §; table I *; | [X]WO03040117 (ORTHO MCNEIL PHARMACEUTICAL CO [US]) [X] 1,9-13 * compounds of table 2, e.g. compound 82; compounds of table I, in particular c. 2, 6-8, 11-15, 22; example 9 *; | [X]US2004009613 (ZHOU MING-MING [US], et al) [X] 1,12,13 * compound of Fig. 13-11, col. 3, row 4; claims 14-20 *; | [X]WO2005037845 (RIGEL PHARMACEUTICALS INC [US], et al) [X] 1,12-15 * claims 26-28; compounds of table 1, in particular compounds 47, 48 at p. 34; compound 184 at p. 27 *; | [X]WO2005040114 (OXAGEN LTD [GB], et al) [X] 1,5,8,13 * claims 16, 20-21 *; | [X]US2005187268 (VON RECHENBERG MORITZ [US], et al) [X] 1,9-13 * §0142; §0029 *; | [X]WO2006047162 (BURNHAM INST [US], et al) [X] 1,9-13 * claims, e.g. claim 19; table I, compound 5858065;example 1, §0092 *; | [X]WO2008057862 (BRISTOL MYERS SQUIBB CO [US], et al) [X] 1,12,13 * compounds 137, 138 at p. 112; compounds 126, 127 at p. 111; compounds 50 and 57 at p. 106; compounds 45 and 47 at p. 105, compound 38-39 *; | [X]WO2008129276 (BOEHRINGER INGELHEIM INT [DE], et al) [X] 1,4,5,7,8,13 * examples 1-3, 5-10, 18-21, 23, 25; claims 27-28 *; | [X]WO2010033986 (UNIV MINNESOTA [US], et al) [X] 1,9-13 * p. 38, second compound; p. 21, l. 1-4 *; | [X]WO2011006158 (UNIV MARYLAND [US], et al) [X] 1,12,13 * p. 91, compound 140; p. 1, middle *; | [X]WO2011133862 (UNIV OREGON HEALTH & SCIENCE [US], et al) [X] 1,8,13 * compound of p. 19; claim 9 *; | [X]EP2484670 (CONSEJO SUPERIOR INVESTIGACION [ES]) [X] 1,9-13* p. 15, table I, first and second compound and p. 16, l. 16 *; | [X] - VALLE PALOMO ET AL, "5-Imino-1,2,4-Thiadiazoles: First Small Molecules As Substrate Competitive Inhibitors of Glycogen Synthase Kinase 3", JOURNAL OF MEDICINAL CHEMISTRY, (20120223), vol. 55, no. 4, doi:10.1021/jm201463v, ISSN 0022-2623, pages 1645 - 1661, XP055061236 [X] 1,10,11,13 * title, abstract; compounds of table 2, e.g. compounds 31, 33, 44, 56 * DOI: http://dx.doi.org/10.1021/jm201463v | International search | [Y]US2005209252 (TENG CHE-MING [TW], et al); | [Y]WO2009070244 (UNIV CORNELL [US], et al); | [Y]US2011201609 (LAWRENCE HARSHANI [US], et al) | Examination | US4786644 | by applicant | US4559157 | US4608392 | US4820508 | US4938949 | US4992478 | US5846514 | US6334997 | WO2009070244 | - DEAN, D., "Recent Advances in the Synthesis and Applications of Radiolabeled Compounds for Drug Discovery and Development", Curr. Pharm. Des., (20000000), vol. 6, no. 10 | - KABALKA, G. et al., "The Synthesis of Radiolabeled Compounds via Organometallic Intermediates", Tetrahedron, (19890000), vol. 45, no. 21, pages 6601 - 21 | - EVANS, E., "Synthesis of radiolabeled compounds", J. Radioanal. Chem., (19810000), vol. 64, no. 1-2, pages 9 - 32 | - KRAFT et al., "Phenotypes of Drosophila brain neurons in primary culture reveal a role for fascin in neurite shape and trajectory", J. Neurosci, (20060000), vol. 26, no. 34, pages 8734 - 47 | - FULGA et al., "Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo", Nat Cell Biol, (20070000), vol. 9, no. 2, doi:doi:10.1038/ncb1528, pages 139 - 48, XP055190554 DOI: http://dx.doi.org/10.1038/ncb1528 | - PINKUS et al., "Fascin, a sensitive new marker for Reed-Sternberg cells of Hodgkin's disease", Am J Pathol, (19970000), vol. 150, no. 2, pages 543 - 562 | - MOSIALOS et al., "Circulating human dendritic cells differentially express high levels of a 55-kd actin-bundling protein", Am. J. Pathol., (19960000), vol. 148, no. 2, pages 593 - 600 | - SAID et al., "The role of follicular and inter digitating dendritic cells in HIV-related lymphoid hyperplasia: localization of fascin", Mod Pathol, (19970000), vol. 10, no. 5, pages 421 - 27 | - MELLER et al., "Ubiquitin proteasome-mediated synaptic reorganization: a novel mechanism underlying rapid ischemic tolerance", J Neurosci, (20080000), vol. 28, no. 1, pages 50 - 9 | - KRAFT et al., J. Neurosci., (20060823), vol. 26, no. 34, pages 8734 - 47 | - PINKUS et al., Am J Pathol, (19970200), vol. 150, no. 2, pages 543 - 62 | - MOSIALOS et al., Am J Pathol, (19960200), vol. 148, no. 2, pages 593 - 600 | - FULGA et al., Nat Cell Biol, (20070200), vol. 9, no. 2, pages 139 - 48 | - SAID et al., Mod Pathol, (19970500), vol. 10, no. 5, pages 421 - 7 | - MELLER et al., J Neurosci, (20080102), vol. 28, no. l, pages 50 - 9 | - FIESER; FIESER, Reagentsfor Organic Synthesis, John Wiley and Sons, (19910000), vol. 1-15 | - RODD, Chemistry of Carbon Compounds, Elsevier Science Publishers, (19890000), vol. 1-5 | - Organic Reactions, John Wiley and Sons, (19910000), vol. 1-40 | - MARCH, Advanced Organic Chemistry, John Wiley and Sons | - ANNA ROGLANS et al., "Diazonium Salts as Substrates in Palladium-Catalyzed Cross-Coupling Reactions", Chem. Rev., (20060000), vol. 106, no. 11, pages 4622 - 4643 | - BRAD M. ROSEN et al., "Nickel-Catalyzed Cross-Couplings Involving Carbon-Oxygen Bonds", Percec Chem. Rev., (20110000), vol. 111, no. 3, pages 1346 - 1416 | - JEAN-PIERRE CORBET et al., "Selected Patented Cross-Coupling Reaction Technologies", Chem. Rev., (20060000), vol. 106, no. 7, doi:doi:10.1021/cr0505268, pages 2651 - 2710, XP055394135 DOI: http://dx.doi.org/10.1021/cr0505268 | - GWILHERM EVANO et al., "Copper-Mediated Coupling Reactions and Their Applications in Natural Products and Designed Biomolecules Synthesis", Chem. Rev., (20080000), vol. 108, no. 8, doi:doi:10.1021/cr8002505, pages 3054 - 3131, XP008151521 DOI: http://dx.doi.org/10.1021/cr8002505 | - BENNY BOGOSLAVSKY et al., "Formation of a Carbon-Carbon Triple Bond by Coupling Reactions In Aqueous Solution", Science, (20050000), vol. 308, no. 5719, pages 234 - 235 | - M. LAFRANCE et al., "Catalytic Intermolecular Direct Arylation of Perfluorobenzenes", J. Am. Chem. Soc., (20060000), vol. 128, no. 27, pages 8754 - 8756 | - NORIO MIYAURA et al., "A new stereospecific cross-coupling by the palladium-catalyzed reaction of 1-alkenylboranes with 1-alkenyl or 1-alkynyl halides", Tetrahedron Letters, (19790000), vol. 20, no. 36, pages 3437 - 3440 | - P.E. FANTA, "The Ullmann Synthesis of Biaryls", Synthesis, (19740000), vol. 1974, pages 9 - 21 | - M. GOMBERG; W. E. BACHMANN, J. Am. Chem. Soc., (19240000), vol. 42, no. 10, pages 2339 - 2343 | - R. J. P. CORRIU; MASSE, J. P., "Activation of Grignard reagents by transition-metal complexes. A new and simple synthesis of trans-stilbenes and polyphenyls", Journal of the Chemical Society, Chemical Communications, (19720000), page 144a | - SHAN, D. et al., "Synthetic analogues of migrastatin that inhibit mammary tumor metastasis in mice", Proc. Nat. Acad. Sci., (20050000), vol. 102, doi:doi:10.1073/pnas.0500658102, pages 3772 - 3776, XP002356046 DOI: http://dx.doi.org/10.1073/pnas.0500658102 | - HANAHAN, D.; WEINBERG, R. A., "The hallmarks of cancer", Cell, (20000000), vol. 100, pages 57 - 70, XP055447752 | - CHRISTOFORI, G., "New signals from the invasive front", Nature, (20060000), vol. 441, doi:doi:10.1038/nature04872, pages 444 - 450, XP002484498 DOI: http://dx.doi.org/10.1038/nature04872 | - WEISS, L., "Metastasis of cancer: a conceptual history from antiquity to the 1990s", Cancer Metastasis Rev, (20000000), vol. 19, no. I-XI, pages 193 - 383 | - FIDLER, I. J., "The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited", Nat Rev Cancer, (20030000), vol. 3, pages 453 - 458 | - VALASTYAN, S.; WEINBERG, R. A., "Tumor metastasis: molecular insights and evolving paradigms", Cell, (20110000), vol. 147, doi:doi:10.1016/j.cell.2011.09.024, pages 275 - 292, XP028317884 DOI: http://dx.doi.org/10.1016/j.cell.2011.09.024 | - FORNIER, M. N., "Approved agents for metastatic breast cancer", Semin Oncol, (20110000), vol. 38, no. 2, pages 3 - 10 | - DAVIES, J. M.; GOLDBERG, R. M., "Treatment of metastatic colorectal cancer", Semin Oncol, (20110000), vol. 38, pages 552 - 560 | - SONDAK, V. K.; HAN, D.; DENEVE, J.; KUDCHADKAR, R., "Current and planned multicenter trials for patients with primary or metastatic melanoma", J Surg Oncol, (20110000), vol. 104, pages 430 - 437 | - PARTIN, A. W.; SCHOENIGER, J. S.; MOHLER, J. L.; COFFEY, D. S., "Fourier analysis of cell motility: correlation of motility with metastatic potential", Proc Natl AcadSci USA, (19890000), vol. 86, pages 1254 - 1258 | - AZNAVOORIAN, S.; MURPHY, A. N.; STETLER-STEVENSON, W. G.; LIOTTA, L. A., "Molecular aspects of tumor cell invasion and metastasis", Cancer, (19930000), vol. 71, pages 1368 - 1383 | - CONDEELIS, J.; SINGER, R. H.; SEGALL, J. E., "The great escape: when cancer cells hijack the genes for chemotaxis and motility", Annu Rev Cell Dev Biol, (20050000), vol. 21, pages 695 - 718 | - ROUSSOS, E. T.; CONDEELIS, J. S.; PATSIALOU, A., "Chemotaxis in cancer", Nat Rev Cancer, (20110000), vol. 11, pages 573 - 587 | - JAFFE, A. B.; HALL, A., "Rho GTPases: biochemistry and biology", Annu Rev Cell Dev Biol, (20050000), vol. 21, pages 247 - 269 | - MATSUDAIRA, P., "Actin crosslinking proteins at the leading edge", Semin Cell Biol, (19940000), vol. 5, doi:doi:10.1006/scel.1994.1021, pages 165 - 174, XP024800084 DOI: http://dx.doi.org/10.1006/scel.1994.1021 | - OTTO, J. J., "Actin-bundling proteins", Curr Opin Cell Biol, (19940000), vol. 6, doi:doi:10.1016/0955-0674(94)90123-6, pages 105 - 109, XP025588259 DOI: http://dx.doi.org/10.1016/0955-0674(94)90123-6 | - MOGILNER, A.; RUBINSTEIN, B., "The physics of filopodial protrusion", Biophys J, (20050000), vol. 89, pages 782 - 795 | - MATTILA, P. K.; LAPPALAINEN, P., "Filopodia: molecular architecture and cellular functions", Nat Rev Mol Cell Biol, (20080000), vol. 9, pages 446 - 454 | - OTTO, J. J.; KANE, R. E.; BRYAN, J., "Formation of filopodia in coelomocytes: localization of fascin, a 58,000 dalton actin cross-linking protein", Cell, (19790000), vol. 17, doi:doi:10.1016/0092-8674(79)90154-5, pages 285 - 293, XP023909413 DOI: http://dx.doi.org/10.1016/0092-8674(79)90154-5 | - BRYAN, J.; KANE, R. E., "Separation and interaction of the major components of sea urchin actin gel", J Mol Biol, (19780000), vol. 125, doi:doi:10.1016/0022-2836(78)90345-5, pages 207 - 224, XP024013556 DOI: http://dx.doi.org/10.1016/0022-2836(78)90345-5 | - YAMASHIRO-MATSUMURA, S.; MATSUMURA, F., "Purification and characterization of an F-actin-bundling 55-kilodalton protein from HeLa cells", JBiol Chem, (19850000), vol. 260, pages 5087 - 5097 | - VIGNJEVIC, D.; YARAR, D.; WELCH, M. D.; PELOQUIN, J.; SVITKINA, T.; BORISY, G. G., "Formation of filopodia-like bundles in vitro from a dendritic network", J Cell Biol, (20030000), vol. 160, pages 951 - 962 | - VIGNJEVIC, D.; KOJIMA, S.; ARATYN, Y.; DANCIU, O.; SVITKINA, T.; BORISY, G. G., "Role of fascin in filopodial protrusion", J Cell Biol, (20060000), vol. 174, doi:doi:10.1083/jcb.200603013, pages 863 - 875, XP055018209 DOI: http://dx.doi.org/10.1083/jcb.200603013 | - ADAMS, J. C., "Roles of fascin in cell adhesion and motility", Curr Opin Cell Biol, (20040000), vol. 16, doi:doi:10.1016/j.ceb.2004.07.009, pages 590 - 596, XP004567200 DOI: http://dx.doi.org/10.1016/j.ceb.2004.07.009 | - TILNEY, L. G.; CONNELLY, P. S.; VRANICH, K. A.; SHAW, M. K.; GUILD, G. M., "Why are two different cross-linkers necessary for actin bundle formation in vivo and what does each cross-link contribute?", J Cell Biol, (19980000), vol. 143, pages 121 - 133 | - DARNEL, A. D.; BEHMOARAM, E.; VOLLMER, R. T.; CORCOS, J.; BIJIAN, K.; SIRCAR, K.; SU, J.; JIAO, J.; ALAOUI-JAMALI, M. A.; BISMAR,, "Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer", Clin Cancer Res, (20090000), vol. I5, pages 1376 - 1383 | - PELOSI, G.; PASINI, F.; FRAGGETTA, F.; PASTORINO, U.; IANNUCCI, A.; MAISONNEUVE, P.; ARRIGONI, G.; DE MANZONI, G.; BRESAOLA, E.; V, "Independent value of fascin immunoreactivity for predicting lymph node metastases in typical and atypical pulmonary carcinoids", Lung Cancer, (20030000), vol. 42, pages 203 - 213 | - HASHIMOTO, Y.; SHIMADA, Y.; KAWAMURA, J.; YAMASAKI, S.; IMAMURA, M., "The prognostic relevance of fascin expression in human gastric carcinoma", Oncology, (20040000), vol. 67, pages 262 - 270 | - CAO, D.; JI, H.; RONNETT, B. M., "Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary", Int J Gynecol Pathol, (20050000), vol. 24, pages 67 - 72, XP009105317 | - RODRIGUEZ-PINILLA, S. M.; SARRIO, D.; HONRADO, E.; HARDISSON, D.; CALERO, F.; BENITEZ, J.; PALACIOS, J., "Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas", Clin Cancer Res, (20060000), vol. 12, pages 1533 - 1539 | - GROTHEY, A.; HASHIZUME, R.; SAHIN, A. A.; MCCREA, P. D., "Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer", Br J Cancer, (20000000), vol. 83, pages 870 - 873 | - HASHIMOTO, Y.; SKACEL, M.; ADAMS, J. C., "Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker?", Int J Biochem Cell Biol, (20050000), vol. 37, doi:doi:10.1016/j.biocel.2005.05.004, pages 1787 - 1804, XP004974392 DOI: http://dx.doi.org/10.1016/j.biocel.2005.05.004 | - MAITRA, A.; IACOBUZIO-DONAHUE, C.; RAHMAN, A.; SOHN, T. A.; ARGANI, P.; MEYER, R.; YEO, C. J.; CAMERON, J. L.; GOGGINS, M.; KERN,, "Immunohistochemical validation of a novel epithelial and a novel stromal marker of pancreatic ductal adenocarcinoma identified by global expression microarrays: sea urchin fascin homo log and heat shock protein 47", Am J Clin Pathol, (20020000), vol. 118, pages 52 - 59 | - YODER, B. J.; TSO, E.; SKACEL, M.; PETTAY, J.; TARR, S.; BUDD, T.; TUBBS, R. R.; ADAMS, J. C.; HICKS, D. G., "The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course", Clin Cancer Res, (20050000), vol. 11, pages 186 - 192 | - ZIGEUNER, R.; DROSCHL, N.; TAUBER, V.; REHAK, P.; LANGNER, C., "Biologic significance of fascin expression in clear cell renal cell carcinoma: systematic analysis of primary and metastatic tumor tissues using a tissue microarray technique", Urology, (20060000), vol. 68, doi:doi:10.1016/j.urology.2006.03.032, pages 518 - 522, XP025075832 DOI: http://dx.doi.org/10.1016/j.urology.2006.03.032 | US19770616921 | US20150617780 |